Form 4: Centessa Pharmaceuticals Grants 165,000 Share Options to Chief Accounting Officer

Centessa Pharmaceuticals plc's Chief Accounting Officer, Raphael Deferiere, was granted 165,000 share options with an exercise price of $13.41, vesting over a multi-year period.

Summary

• Raphael Deferiere, the Chief Accounting Officer of Centessa Pharmaceuticals plc (CNTA), acquired 165,000 share options.
• The options have an exercise price of $13.41 per share.
• The transaction date for this option grant was June 2, 2025.
• The vesting schedule dictates that 25% of the options will vest and become exercisable on June 2, 2026.
• The remaining 75% of the options will vest in 36 equal monthly installments starting from July 1, 2026.
• The share options are set to expire on June 2, 2035.

Sentiment

Score: 7

Explanation: The grant of a significant number of share options to a key executive is generally a positive signal, indicating alignment of interests and a long-term commitment from management. It reflects standard corporate governance practice for incentivizing executives.

Positives

• The grant of 165,000 share options to a key executive like the Chief Accounting Officer aligns management's long-term interests with those of shareholders.
• The significant number of options provides a substantial incentive for the executive to contribute to the company's future growth and stock performance.

Risks

• The value of the granted options is contingent upon Centessa Pharmaceuticals plc's stock price exceeding the exercise price of $13.41 per share in the future.
• If the company's stock price does not perform favorably, the options may not become 'in the money' or could lose their potential value.

Future Outlook

The long-term vesting schedule of the option grant, extending over several years, suggests a strategic focus on executive retention and aligning management's incentives with the company's sustained future growth and performance.

Management Comments

• The filing is a standard regulatory disclosure and does not contain direct quotes from management, but it is signed by Gregory Weinhoff as attorney-in-fact for Raphael Deferiere.

Industry Context

Option grants are a prevalent form of executive compensation within the biotechnology and pharmaceutical sectors. This practice aims to incentivize long-term performance and align executive interests with shareholder value creation, which is particularly relevant given the extended development cycles and inherent risks in the industry.

Comparison to Industry Standards

• The grant of 165,000 options to a Chief Accounting Officer represents a significant component of executive compensation, which is common for companies of Centessa's size and stage in the biotech industry. Executive compensation packages in this sector frequently include substantial equity components to attract and retain high-caliber talent.
• This Form 4 filing focuses solely on the transaction and does not provide specific details for direct comparisons to other companies' projects or results.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also potential benefit from aligned management incentives leading to increased share value.
• Employees: No direct impact mentioned, but executive compensation practices can influence overall company culture and compensation philosophy.

Next Steps

• Continued vesting of the granted share options according to the specified schedule.
• Potential exercise of options by Raphael Deferiere upon vesting and if market conditions are favorable.

Key Dates

Keywords

Centessa Pharmaceuticals, CNTA, Form 4, SEC filing, insider transaction, share options, stock options, executive compensation, Raphael Deferiere, Chief Accounting Officer, beneficial ownership